Fenbendazole as a Cancer Therapy in Humans
Fenbendazole does not target your symptoms, it attacks and kills cancer cells.
Fenbendazole safely targets metabolic pathways in cancer cells. It attacks cancer at multiple points. It can weaken and kill the cancer cells. The drug is an affordable, low-toxicity solution for today’s cancer treatment. Despite no FDA approval for treating cancer, existing animal and in vitro studies show that Fenbendazole exhibits promising anticancer properties, including:
Inhibiting glycolysis
Down-regulating glucose uptake
Inducing oxidative stress
Enhancing apoptosis in cancer cells
May not be affected by drug resistance
Lower toxicity
‘In vitro’ studies are tests done in a lab and use cells, tissues, or isolated organs instead of living animals or people.
Fenbendazole starves the cancer cells of energy by interfering with glucose metabolism.
It prevents cancer cells from dividing by disrupting the cells’ microtubule formation.
It activates tumor-suppressor pathways, including the p53 gene, which plays a vital role in maintaining genomic stability and preventing cancer development. (The covid-19 vaccine suppressed the p53 gene)
Fenbendazole has been shown to target certain cancer cells and be less toxic to surrounding healthy tissues. The drug presents a lower level of toxicity compared to other cancer treatment options, and under proper supervision, can be used alongside conventional cancer treatments. Fenbendazole has demonstrated efficacy against chemotherapy-resistant cancer cells and has shown potential to overcome drug resistance.
While fenbendazole was initially formulated for veterinary use, preliminary research suggests that fenbendazole may inhibit cancer cell growth and induce cancer cell death through various mechanisms, such as disruption of microtubule formation and inhibition of glucose uptake. * https://www.healthline.com/health/pancreatic-cancer/fenbendazole-for-pancreatic-cancer
Fenbendazole has been identified as a critical component in targeting cancer’s metabolic vulnerabilities. Due to its ability to destabilize microtubules, fenbendazole demonstrates strong potential as an anticancer agent. By inhibiting tubulin polymerization, fenbendazole constitutes a vital element in disrupting cancer cell division. Additionally, the drug functions synergistically alongside traditional cancer treatment such as chemotherapy.
A 2020 study at Stanford University examined the use of fenbendazole as an adjunct therapy for enhancing anti-cancer effects in cancer patients. The University’s results indicated that fenbendazole may improve treatment outcomes, including reducing tumor size and enhancing the effectiveness of conventional chemotherapy. The inclusion of low-cost fenbendazole in patient treatments improved efficacy, reduced tumor size, reduced toxic side effects, and improved patient treatment outcomes. *Chiang RS, Syed AB, Wright JL, Montgomery B, Srinivas S (2021) Fenbendazole Enhancing Anti-Tumor Effect: A Case Series. Clin Oncol Case Rep 4:2
Preclinical Studies on Fenbendazole and Cancer
Most of the research on Fenbendazole and its anticancer potential has been conducted in preclinical studies, meaning experiments on cell cultures and animal models. While these studies have shown some promising results, it is important for us all to understand that preclinical data doesn’t always translate to human success.
Unlike Fenbendazole, Mebendazole, and Albendazole—all from the Benzimidazole family—have been tested in several clinical trials with cancer patients. *Fenbendazole For Cancer: Research, Trials & Potential https://healnavigator.com/blog/fenbendazole-cancer-clinical-trials/
Preclinical studies demonstrate how fenbendazole disrupts cancer cell growth. However, the lack of medical oversight and proper dosing guidelines may increase the possibility of drug interaction and liver toxicity. These are two factors that should be monitored during any fenbendazole protocol. Monitored patients’ reports indicate that fenbendazole has low toxicity and confirmed therapeutic efficacy in cancer care.
As cancer diagnoses rise globally, the urgency for innovative, effective, and supportive therapies grows stronger. A recent peer-reviewed study has highlighted a groundbreaking protocol combining ivermectin, Fenbendazole, and natural compounds such as Vitamin E, curcumin, and CBD. These elements, when used together, demonstrate significant potential in supporting cancer care. *Low-Toxin BioEnergetic Forum, Alleged Cancer Cure https://lowtoxinforum.com/threads/alleged-cancer-cure.27459/page-4
Drug repositioning is a strategy for identifying new antitumor drugs; it allows existing, approved clinical drugs to be repurposed to treat tumors. Based on the similarities between parasitic diseases and cancer, recent studies aimed to investigate the efficacy of existing antiparasitic drugs in cancer. *Li YQ, Zheng Z, Liu QX, et al. Repositioning of Antiparasitic Drugs for Tumor Treatment. Front Oncol. 2021;11:670804. Published 2021 Apr 29. doi:10.3389/fonc.2021.670804 https://pmc.ncbi.nlm.nih.gov/articles/PMC8117216/
Various studies in cell lines and animals have demonstrated the efficacy of fenbendazole in inhibiting tumor growth and targeting drug-resistant cancer cells by inhibiting glycolysis. *https://ar.iiarjournals.org/content/anticanres/44/9/3725.full.pdf
Despite the lack of regulatory approval and extensive clinical trials for fenbendazole as a cancer treatment in humans, some cancer patients have self-administered the drug, as documented in case studies. Table IV discusses four case reports where fenbendazole has led to a reduction in tumor size and two cases where patients experienced drug-related hepatic dysfunction. In both cases, despite the hepatotoxicity, patients’ liver function recovered rapidly upon discontinuing fenbendazole. Due to its accessibility over the counter at a relatively low price, patients have turned to fenbendazole as an at-home treatment for cancer. As the published case reports observed, the most common self-administered regimen involves taking 1 gram of fenbendazole orally once daily for three consecutive days, followed by four days off treatment. However, the use of fenbendazole for cancer therapy in humans requires further pilot and extensive clinical trials to establish effective doses and regimens. Patients with compromised liver function, liver cirrhosis, or liver cancer should use fenbendazole with caution. Additionally, combining fenbendazole with glycolysis inhibitors and hepatoprotective pharmaceutical or nutraceutical agents can lead to synergic therapeutic activity while reducing potential liver toxicity. *https://ar.iiarjournals.org/content/anticanres/44/9/3725.full.pdf
Table IV
*https://ar.iiarjournals.org/content/anticanres/44/9/3725.full.pdf
Benzimidazoles were identified from a screen that selectively targets highly metastatic prostate cancer cells but is not toxic to normal cells. We determined that the preferential antitumor activity of these agents was mediated in part through cell-cycle arrest and induction of apoptosis, both in vitro and in vivo. We further demonstrate that benzimidazole treatment prolongs the survival of mice bearing prostate cancer lung metastases and inhibits the growth of prostate cancer cells growing in the bone microenvironment. More strikingly, these anti-tumor effects remain active against prostate cancer cells that are resistant to paclitaxel, the standard chemotherapy for men with advanced prostate cancer, both in vitro and in vivo. Our study further supports the use of benzimidazoles as a potential anti-cancer therapy for men with metastatic prostate cancer.
*Benzimidazole as Novel Therapy for Hormone-Refractory Metastic Prostate Cancer, May 2011; Prepared for: The U.S. Army Medical Research and Materiel Command, Fort Detrick, Maryland 21702-5012 https://apps.dtic.mil/sti/tr/pdf/ADA545657.pdf